AR127484A1 - Compuestos y métodos dirigidos a interleucina-34 - Google Patents
Compuestos y métodos dirigidos a interleucina-34Info
- Publication number
- AR127484A1 AR127484A1 ARP220102931A ARP220102931A AR127484A1 AR 127484 A1 AR127484 A1 AR 127484A1 AR P220102931 A ARP220102931 A AR P220102931A AR P220102931 A ARP220102931 A AR P220102931A AR 127484 A1 AR127484 A1 AR 127484A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- targetting
- interleukin
- compounds
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163273216P | 2021-10-29 | 2021-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127484A1 true AR127484A1 (es) | 2024-01-31 |
Family
ID=84367272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102931A AR127484A1 (es) | 2021-10-29 | 2022-10-27 | Compuestos y métodos dirigidos a interleucina-34 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11976114B2 (enExample) |
| EP (1) | EP4423127A1 (enExample) |
| JP (3) | JP7622019B2 (enExample) |
| KR (1) | KR20240099349A (enExample) |
| CN (1) | CN118475610A (enExample) |
| AR (1) | AR127484A1 (enExample) |
| AU (1) | AU2022376940A1 (enExample) |
| CA (1) | CA3236555A1 (enExample) |
| CL (1) | CL2024001303A1 (enExample) |
| CO (1) | CO2024005417A2 (enExample) |
| CR (1) | CR20240170A (enExample) |
| DO (1) | DOP2024000076A (enExample) |
| EC (1) | ECSP24032906A (enExample) |
| IL (1) | IL312380A (enExample) |
| MX (1) | MX2024005153A (enExample) |
| PE (1) | PE20241471A1 (enExample) |
| TW (1) | TW202336034A (enExample) |
| WO (1) | WO2023076995A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4472679A1 (en) * | 2022-02-03 | 2024-12-11 | Eli Lilly and Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5828762B2 (ja) | 2008-07-21 | 2015-12-09 | プロビオドルグ エージー | 診断用抗体アッセイ |
| EP2576617B1 (en) | 2010-06-04 | 2016-04-27 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| LT3042917T (lt) | 2010-08-12 | 2018-05-10 | Eli Lilly And Company | Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| BR112014018961A8 (pt) | 2012-02-06 | 2017-07-11 | Genentech Inc | Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado |
| KR20170031245A (ko) | 2014-07-28 | 2017-03-20 | 노그라 파마 리미티드 | 염증성 장 질환을 진단 및 치료하기 위한 방법 및 조성물 |
| WO2016097420A1 (en) | 2014-12-19 | 2016-06-23 | Universite De Nantes | Anti il-34 antibodies |
| ES3012402T3 (en) * | 2015-04-13 | 2025-04-09 | Pfizer | Therapeutic antibodies and their uses |
| EP3302552A1 (en) | 2015-06-02 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| US10988529B2 (en) * | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| EP3758736B1 (en) | 2018-03-02 | 2024-05-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Il-34 for use in a method of treating retinal inflammation and neurodegeneration |
| EA202192888A1 (ru) | 2019-05-31 | 2022-03-23 | Эли Лилли Энд Компани | Соединения и способы нацеливания на тау человека |
| AR121898A1 (es) * | 2020-04-30 | 2022-07-20 | Lilly Co Eli | Compuestos y métodos dirigidos a interleucina-34 |
-
2022
- 2022-10-27 TW TW111140796A patent/TW202336034A/zh unknown
- 2022-10-27 KR KR1020247017337A patent/KR20240099349A/ko active Pending
- 2022-10-27 AU AU2022376940A patent/AU2022376940A1/en active Pending
- 2022-10-27 IL IL312380A patent/IL312380A/en unknown
- 2022-10-27 WO PCT/US2022/078776 patent/WO2023076995A1/en not_active Ceased
- 2022-10-27 US US18/050,227 patent/US11976114B2/en active Active
- 2022-10-27 EP EP22814582.7A patent/EP4423127A1/en active Pending
- 2022-10-27 CN CN202280086946.7A patent/CN118475610A/zh active Pending
- 2022-10-27 PE PE2024000938A patent/PE20241471A1/es unknown
- 2022-10-27 JP JP2022172479A patent/JP7622019B2/ja active Active
- 2022-10-27 CA CA3236555A patent/CA3236555A1/en active Pending
- 2022-10-27 MX MX2024005153A patent/MX2024005153A/es unknown
- 2022-10-27 CR CR20240170A patent/CR20240170A/es unknown
- 2022-10-27 AR ARP220102931A patent/AR127484A1/es unknown
-
2024
- 2024-04-05 US US18/628,082 patent/US20240309082A1/en active Pending
- 2024-04-17 JP JP2024066552A patent/JP2024091777A/ja active Pending
- 2024-04-26 CL CL2024001303A patent/CL2024001303A1/es unknown
- 2024-04-26 DO DO2024000076A patent/DOP2024000076A/es unknown
- 2024-04-26 CO CONC2024/0005417A patent/CO2024005417A2/es unknown
- 2024-04-29 EC ECSENADI202432906A patent/ECSP24032906A/es unknown
-
2025
- 2025-01-15 JP JP2025005276A patent/JP2025063187A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023076995A1 (en) | 2023-05-04 |
| JP2023067832A (ja) | 2023-05-16 |
| CR20240170A (es) | 2024-05-24 |
| PE20241471A1 (es) | 2024-07-17 |
| US11976114B2 (en) | 2024-05-07 |
| CO2024005417A2 (es) | 2024-05-30 |
| KR20240099349A (ko) | 2024-06-28 |
| CL2024001303A1 (es) | 2024-08-30 |
| US20240309082A1 (en) | 2024-09-19 |
| ECSP24032906A (es) | 2024-05-31 |
| JP2024091777A (ja) | 2024-07-05 |
| CN118475610A (zh) | 2024-08-09 |
| TW202336034A (zh) | 2023-09-16 |
| MX2024005153A (es) | 2024-05-13 |
| DOP2024000076A (es) | 2024-06-16 |
| US20230279094A1 (en) | 2023-09-07 |
| IL312380A (en) | 2024-06-01 |
| JP2025063187A (ja) | 2025-04-15 |
| EP4423127A1 (en) | 2024-09-04 |
| AU2022376940A1 (en) | 2024-05-02 |
| JP7622019B2 (ja) | 2025-01-27 |
| CA3236555A1 (en) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22084245A (es) | Compuestos y métodos dirigidos a interleucina-34 | |
| DOP2022000194A (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| CO2020014575A2 (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos | |
| UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
| CL2019000266A1 (es) | Composición de cannabis. | |
| WO2018224063A3 (en) | FORMS IN THE SOLID STATE OF ELAGOLIX | |
| CO2018002060A2 (es) | Compuestos farmacéuticos | |
| CO2019007830A2 (es) | Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas | |
| BR112016026809A2 (pt) | compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr | |
| JOP20220119A1 (ar) | أجسام مضادة trem2 واستخداماتها | |
| CR20170344A (es) | Anticuerpos para tau y usos de los mismos | |
| UY37378A (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus | |
| EA201892216A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| DOP2021000229A (es) | Materiales y métodos para modular la inmunidad mediada por cédula t | |
| CL2020000070A1 (es) | Agentes, usos y métodos para el tratamiento. | |
| MX392158B (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| MX2020006105A (es) | Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| BR112022014160A2 (pt) | Fatores de transcrição de proteína dedo de zinco para reprimir a expressão de tau | |
| MA39337B1 (fr) | Modulateurs de pyrazines de gpr6 | |
| MX2021015501A (es) | Anticuerpos y metodos de uso. | |
| AR127484A1 (es) | Compuestos y métodos dirigidos a interleucina-34 | |
| SA520420046B1 (ar) | مركبات بيريدازينون ثلاثية الحلقة مندمجة وعقاقير أولية منها مفيدة لعلاج الإصابات الفيروسة المخاطية القويمة | |
| MX2024005145A (es) | Compuestos y metodos dirigidos a la interleucina-34. |